China Bozza Development Holdings Limited (1069) AI Stock Analysis

• Market Cap: HK$39.63M
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): 8.2
• Beta (1Y): 1.22
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 33
• Sector: Basic Materials
• Sector Strength: 66
• Industry: Paper, Lumber & Forest Products
• EPS (TTM): 0.07
• Shares Outstanding: 102,924,220
• 10 Day Avg. Volume: 1,122,384
• 30 Day Avg. Volume: 1,328,670
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$0.50
• Price Target Upside: 31.58% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: HK$0.50 ▲(31.58% Upside)

The company's financial instability, characterized by high leverage and inconsistent cash flows, is the most significant factor affecting its stock score. Technical indicators also suggest bearish momentum. While the valuation appears attractive, the lack of a dividend yield and overall financial health concerns weigh heavily on the stock's attractiveness.

China Bozza Development Holdings Limited Business Overview & Revenue Model

Company Description

China Health Technology Group Holding Co., Ltd. is an investment company, which engages in the business of forestry management. It engages in the plantation, logging, and sale of timbre related products. The company was founded on October 8, 2009 and is headquartered in Shenzhen, China.

How the Company Makes Money

China Bozza Development Holdings Limited generates revenue primarily through the development and sale of real estate properties. The company's key revenue streams include the sale of residential units, leasing of commercial properties, and management fees from property management services. Additionally, the company may engage in strategic partnerships with local governments or other real estate developers to enhance its project portfolio and access larger markets. Revenue is further supported by investments in real estate projects that yield rental income and potential capital gains from property value appreciation.

China Bozza Development Holdings Limited Financial Statement Overview

Summary

China Bozza Development Holdings Limited faces significant financial challenges with unstable revenue, high leverage, and fluctuating cash flow. Despite recent improvements in net income and free cash flow, these are overshadowed by a high debt burden and past negative equity, posing risks to financial health.

Income Statement

The company's revenue has fluctuated significantly, with a decline from 2023 to 2024. Gross profit margins are very low, and EBIT margins are negative, indicating operational challenges. However, there is a positive net income in 2024, largely driven by significant EBITDA, suggesting non-operational factors may be influencing profitability.

Balance Sheet

The balance sheet shows high leverage, with a debt-to-equity ratio that is concerning due to negative equity in recent years. While stockholders' equity improved in 2024, the equity ratio remains low due to high liabilities. Overall, the company's financial stability is at risk, given the high debt levels.

Cash Flow

The company has demonstrated positive free cash flow in 2024, with growth from the previous year. Operating cash flow remains strong relative to net income, indicating efficient cash management. However, the historical volatility in cash flows suggests potential risks in maintaining this trend.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Dec 2020	Dec 2019
Income Statement
Total Revenue	47.61M	58.72M	6.76M	6.67M	54.25M
Gross Profit	1.90M	11.51M	0.00	6.67M	34.81M
EBITDA	208.39M	-42.17M	-9.85M	-48.36M	18.65M
Net Income	200.01M	-10.80M	-18.90M	-268.54M	-340.48M
Balance Sheet
Total Assets	178.17M	140.64M	93.52M	491.54M	588.51M
Cash, Cash Equivalents and Short-Term Investments	3.23M	4.33M	1.11M	134.00K	3.18M
Total Debt	119.11M	356.77M	321.97M	333.44M	313.10M
Total Liabilities	165.20M	457.35M	400.15M	369.48M	336.27M
Stockholders Equity	12.96M	-316.71M	-306.63M	122.06M	252.24M
Cash Flow
Free Cash Flow	28.63M	22.16M	-466.00K	-5.58M	-9.97M
Operating Cash Flow	28.86M	23.44M	-466.00K	-5.58M	-9.73M
Investing Cash Flow	-26.49M	-23.26M	2.00K	-410.00K	283.00K
Financing Cash Flow	-3.47M	3.04M	-249.00K	-3.29M	7.13M

China Bozza Development Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1069, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.43, and below the 200-day MA of 0.43, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.50 is Neutral, neither overbought nor oversold. The STOCH value of 5.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1069.

China Bozza Development Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2002	64 Neutral	HK$1.96B	10.45	3.56%	2.72%	-5.66%	-56.96%
Sector *	62 Neutral	$10.36B	6.35	0.80%	2.84%	3.10%	-36.03%
3363	58 Neutral	HK$195.00M	7.60	2.13%	5.64%	0.80%	81.27%
1069	47 Neutral	HK$39.63M	8.23	17.22%	―	―	―
SCD1	―	€535.03M	―		―	―	―
0731	47 Neutral	HK$263.12M	15.25	11.34%	―	-9.44%	―
0794	46 Neutral	HK$60.92M	27.06	0.44%	―	-0.53%	―

China Bozza Development Holdings Limited Corporate Events

China Bozza Completes Successful Share Placement

China Bozza Development Holdings Limited has successfully completed the placement of 17,000,000 new shares under a general mandate, representing approximately 16.52% of the company’s enlarged share capital. The placement raised net proceeds of approximately HK$4.63 million, which will be allocated towards rental expenses, staff costs, and professional fees. This strategic move aims to strengthen the company’s financial position and operational capabilities without altering the substantial shareholder structure.

China Bozza Development Announces Share Placement for Capital Boost

China Bozza Development Holdings Limited has announced a placing agreement with Cheong Lee Securities Limited to issue up to 17,000,000 new shares at HK$0.28 each, representing a significant discount to recent trading prices. The net proceeds of approximately HK$4.63 million will be used for general working capital, potentially impacting the company’s financial flexibility and market positioning.

China Health Technology Group Approves Share Consolidation

China Health Technology Group Holding Company Limited announced the successful passing of a resolution at its Extraordinary General Meeting held on July 4, 2025, approving a share consolidation. The share consolidation will take effect on July 8, 2025, with new share certificates issued in gold color, impacting trading and settlement processes. This move is expected to streamline the company’s share structure, potentially enhancing market perception and operational efficiency.

China Health Technology Announces Share Consolidation Plan

China Health Technology Group Holding Company Limited has announced an extraordinary general meeting (EGM) to discuss a proposed share consolidation. The company plans to consolidate every ten issued and unissued ordinary shares into one share, which could impact shareholder value and market perception. The move is subject to approval from the Hong Kong Stock Exchange and compliance with Cayman Islands laws. This consolidation aims to streamline the company’s share structure, potentially enhancing its market positioning and operational efficiency.

China Bozza Proposes Share Consolidation and Board Lot Size Change

China Bozza Development Holdings Limited has announced a proposed share consolidation and change in board lot size. The company plans to consolidate every ten existing shares into one consolidated share, reducing the number of shares in issue from 859,242,204 to 85,924,220, while maintaining the authorized share capital at HK$100,000,000. Additionally, the board lot size for trading on the Stock Exchange will change from 16,000 existing shares to 10,000 consolidated shares. This move is intended to streamline the company’s share structure without affecting its financial position or shareholder rights.

China Health Technology Group Partners with Jianzhi Tang for Health Product Expansion

China Health Technology Group Holding Company Limited has entered into a strategic cooperation memorandum with Heilongjiang Jianzhi Tang Biotechnology Co., Ltd. to collaborate on the research, development, and sales of lingzhi products and health supplements. This partnership aims to leverage Jianzhi Tang’s technological strengths to expand the company’s health product offerings, enhancing business diversification and creating new profit growth drivers. The collaboration is expected to improve the company’s financial performance and profitability, benefiting shareholders. The memorandum serves as a framework for future agreements, with both parties planning market analysis and industry research to support the initiative.